Table 4.
Responding Member States with HCV testing guidance for PWID, by region and ranked according to estimated number of PWID.1
|
Region (N1 = number of countries within region)1 |
Estimated number of PWID (95% UI)1 |
Population prevalence of PWID (95% UI)1 |
Responding Member States N2 (% of N1) |
Responding Member States with testing guidance for PWID N3 (% of N2) |
|---|---|---|---|---|
| East and Southeast Asia (16) | 3,989,000 (3,041,000–4,955,000) | 0.25% (0.19–0.31) | 15 (94%) | 8 (53%) |
| Eastern Europe (17) | 3,020,000 (1,653,500–5,008,000) | 1.30% (0.71–2.15) | 14 (82%) | 10 (71%) |
| North America (2) | 2,557,000 (1,498,500–4,428,000) | 1.06% (0.62–1.83) | 2 (100%) | 2 (100%) |
| Latin American (20) | 1,823,000 (1,392,000–2,380,000) | 0.46% (0.35–0.60) | 12 (60%) | 2 (17%) |
| Sub-Saharan Africa (47) | 1,378,000 (645,500–3,080,000) | 0.28% (0.13–0.62) | 27 (58%) | 3 (11%) |
| South Asia (9) | 1,023,500 (783,500–1,263,000) | 0.09% (0.07–0.11) | 6 (67%) | 4 (67%) |
| Western Europe (28) | 1,009,500 (686,500–1,386,500) | 0.34% (0.23–0.47) | 24 (86%) | 19 (79%) |
| Middle East and North Africa (21) | 349,500 (177,500–521,500) | 0.12% (0.06–0.18) | 17 (81%) | 9 (53%) |
| Central Asia (5) | 281,500 (189,500–416,500) | 0.63% (0.43–0.94) | 5 (100%) | 3 (60%) |
| Australasia (2) | 115,500 (83,000–148,000) | 0.59% (0.42–0.75) | 2 (100%) | 2 (100%) |
| Caribbean (13) | 79,500 (53,000–118,000) | 0.44% (0.30–0.66) | 5 (39%) | 0 (0%) |
| Pacific Island States and Territories (12) | 22,500 (15,000–33,500) | 0.33% (0.22–0.49) | 6 (50%) | 0 (0%) |
| Global (194) | 15,648,000 (10,219,000–23,737,500) | 0.33% (0.21–0.49) | 135 (70%) | 62 (46%) |
HCV, hepatitis C virus; PWID, people who inject drugs; WHO, World Health Organization.
1
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Heal. 2017. 5:e1192-207.